Skyrizi subcutaneous induction dosing for Crohn's disease is expected to become available later this fall, subject to approval, supporting a more convenient frontline IBD option and a 2027 uptake inflection.
Rinvoq is entering new dermatology indications, with U.S. approval decisions expected later in 2026 for vitiligo and early 2027 for alopecia areata.
AbbVie expects U.S. approval and launch of tavapadon in third-quarter 2026, adding an oral Parkinson's therapy to Vyalev and Duopa.
AbbVie expects BoE, a fast-acting short-duration toxin, to expand the aesthetics toxin market and potentially complement Botox in the U.S. after international launches.
AbbVie expects to close its Apogee Therapeutics acquisition in third-quarter 2026, adding long-acting immunology assets in dermatology, respiratory and related inflammatory diseases.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for AbbVie Inc. and 4,900+ companies.